Last updated on August 2019

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Brief description of study

The objectives of this study are to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of participants with moderate to severe plaque psoriasis.

Clinical Study Identifier: NCT03875508

Find a site near you

Start Over

Dermatology Physicians of CT /ID# 210637

Shelton, CT United States
  Connect »